1
Open
[.]
2
Close
[.]
3
Allotment
—
4
Listing
[.]
Issue Size
37,00,000 shares (agg. up to ₹[.] Cr)
Listing Date
[.]
✦ AI Insight
Restated Financials (₹ Cr.)
| Period Ended | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|
| Assets | 36.36 | 41.19 | 23.63 |
| Total Income | 40.86 | 33.30 | 23.15 |
| Profit After Tax | 4.87 | 5.17 | 3.83 |
| NET Worth | 28.99 | 13.42 | 9.24 |
| Reserves and Surplus | 18.83 | 12.42 | 8.24 |
| Amount in ₹ Crore |
Peer Comparison
| Company | Issue Type | Issue Size | Issue Price | PE Ratio | Listing Day Close | Listing Gain/Loss % | LTP |
|---|---|---|---|---|---|---|---|
| Bio Medica Laboratories Ltd. | SME | ₹52.43 Cr | ₹139 | 13.03 | ₹115.80 | -16.69% | ₹138.70 (-0.18%) |
| Goldline Pharmaceutical Ltd. | SME | ₹11.61 Cr | ₹43 | 10.47 | ₹56.77 | +32.02% | ₹38.13 (-4.65%) |
| Speciality Medicines Ltd. | SME | ₹29.14 Cr | ₹124 | 9.27 | ₹125.90 | +1.53% | ₹185.00 (+0.00%) |
| Accretion Nutraveda Ltd. | SME | ₹24.77 Cr | ₹129 | 26.27 | ₹191.20 | +48.22% | ₹273.75 (+0.09%) |
| KRM Ayurveda Ltd. | SME | ₹77.49 Cr | ₹135 | 17.32 | ₹180.70 | +33.85% | ₹255.30 (+2.51%) |
| Curis Lifesciences Ltd. | SME | ₹27.52 Cr | ₹128 | 12.44 | ₹141.00 | +10.16% | ₹112.00 (+1.82%) |
| Aptus Pharma Ltd. | SME | ₹13.02 Cr | ₹70 | 11.29 | ₹84.84 | +21.20% | ₹254.50 (+1.13%) |
| Hexagon Nutrition Ltd. | Mainboard | ₹138.87 Cr | ₹45 | 22.69 | ₹53.19 | +18.20% | ₹65.51 (+1.93%) |
| Sai Parenteral's Ltd. | Mainboard | ₹408.79 Cr | ₹392 | 72.19 | ₹405.70 | +3.49% | ₹535.60 (-0.34%) |
| Corona Remedies Ltd. | Mainboard | ₹655.37 Cr | ₹1062 | 43.47 | ₹1,438.40 | +35.44% | ₹2,113.00 (+4.28%) |
| Rubicon Research Ltd. | Mainboard | ₹1,377.50 Cr | ₹485 | 55.75 | ₹628.20 | +29.53% | ₹1,520.20 (-0.78%) |
| Amanta Healthcare Ltd. | Mainboard | ₹126.00 Cr | ₹126 | 34.59 | ₹141.75 | +12.50% | ₹163.00 (-0.61%) |
| Anlon Healthcare Ltd. | Mainboard | ₹121.03 Cr | ₹91 | 17.67 | ₹91.73 | +0.80% | ₹15.01 (-0.40%) |
Objects of the Issue
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Purchase of Plant & Machinery for Setting up of Cold Storage Facility | 4.42 |
| 2 | Design, Development & Maintenance of Mobile Application | 3.98 |
| 3 | Advertisement and Digital Marketing Activities | 0.66 |
| 4 | Working Capital Requirements | 21.37 |
| 5 | General Corporate Purposes |
About GNH India Pharmaceuticals IPO
Incorporated in , GNH India Pharmaceuticals Limited engaged in the business of sourcing, distributing, and delivering a comprehensive range of pharmaceutical products, including orphan drugs, biologics, biosimilars, vaccines, and comparator drugs for clinical trials. With a portfolio of over 135,000 product lines sourced from more than 250 suppliers and 110 distributors across key pharmaceutical markets worldwide, the company caters to the entire spectrum of pharmaceutical trade, including wholesale, tender supplies, and name patient access. The company exports to over 180 countries and has established a strong presence in markets like the USA, Canada, Europe, and the Middle East. Services: Cold Chain Shipment: The company follows WHO-GSDP guidelines with cold chain systems to ensure temperature-controlled medicine handling. Name Patient Supply: The company sources rare, special medications globally to ensure timely access for patients with rare diseases. Orphan Drugs: The company ensures access to orphan drugs for rare diseases through global sourcing and regulatory expertise. RLD (Reference Listed Drug): The company supplies clinical trial products and trusted RLDs for diverse th
Contact Details
GNH India Pharmaceuticals Ltd. AddressUnit No.14, 15, 16, 17, Ground Floor, PrabhadeviIndustrial Estate, Enterprises Industrial Premises408, Veer Sawarkar Road, Prabhadevi,Mumbai, Maharashtra, 400025022-62706900info@gnhindia.comVisit Website